Sample CME manuscript submission: Response to the article by Pham et al entitled "Review BRAF inhibition and the spectrum of granulomatous reactions"

Marion Marcaillou; Jeremie Dion; Barouyr Baroudjian; Emilien Ezrine; Cristina Carrera; Alisa Anderle; Zoe Apalla; Azael Freites-Martinez; Cécile Pages; Celeste Lebbe; Nicolas Meyer; Vincent Sibaud; Thibault Comont

doi:10.1016/j.jaad.2022.04.053

Sample CME manuscript submission: Response to the article by Pham et al entitled "Review BRAF inhibition and the spectrum of granulomatous reactions"

J Am Acad Dermatol. 2022 Aug;87(2):e85-e88. doi: 10.1016/j.jaad.2022.04.053. Epub 2022 May 5.

Authors

Affiliations

¹ Department of Onco-Dermatology, Institut universitaire du cancer de Toulouse, Toulouse, France. Electronic address: marion.marcaillou@orange.fr.
² Department of Internal Medicine, Institut universitaire du cancer de Toulouse, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III - Paul Sabatier, Toulouse, France.
³ Department of Dermatology, Université Paris Cité, AP - HP Saint Louis Hospital, Paris, France.
⁴ Department of Dermatology, Hospital Clinic Barcelona, University of Barcelona, Centro de Investigacion en Red de Enfermedades Raras, Institudo de Salud Carlos III, Barcelona, Spain.
⁵ Department of Dermatology, Düsseldorf Hospital, Düsseldorf, Germany.
⁶ Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁷ Department of Dermatology, Hospital Ruber Juan Bravo and Universidad European, Madrid, Spain.
⁸ Department of Onco-Dermatology, Institut universitaire du cancer de Toulouse, Toulouse, France.

PMID: 35526651
DOI: 10.1016/j.jaad.2022.04.053

No abstract available

Keywords: BRAF inhibitor; cobimetinib granuloma; dabrafenib; encorafenib MEK inhibitor; granulomatous reaction; melanoma; sarcoidosis; trametinib; vemurafenib.

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology
Humans
Melanoma* / drug therapy
Mutation
Oximes / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Pyridones / therapeutic use
Skin Neoplasms* / drug therapy
Vemurafenib / therapeutic use

Substances

Oximes
Protein Kinase Inhibitors
Pyridones
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf